IE 11 is a very old Browser and it`s not supported on this site
Remuneration Report

Remuneration Report

This remuneration report for the fiscal year 2020 outlines the remuneration system as well as the remuneration of the members of the Board of Directors of BB Biotech AG. The content and scope of the information contained in this report is in accordance with the provisions of the Ordinance Against Excessive Compensation in Public Corporations (the Ordinance) and with the Directive on Information relating to Corporate Governance (DCG) of the SIX Swiss Exchange.

1. Responsibilities and authorities with respect to remuneration

1. Responsibilities and authorities with respect to remuneration

1.1 Introductory remarks relating to the specific structure of BB Biotech AG as an investment company

The Board of Directors of BB Biotech AG has not made use of its competence to delegate the executive management of all or part of the Company’s business pursuant to article 716b CO and therefore manages the business of the Company itself, to the extent it has not been delegated to the investment manager within the framework of the management contract. Accordingly, BB Biotech AG does not have an executive management pursuant to article 716b CO or the Ordinance.

For details, please refer to note 7.

1.2 Responsibilities and authorities with respect to the remuneration

The Remuneration and Nomination Committee is responsible for ensuring that the process relating to the determination of the remuneration is held on a fair and transparent basis and that such process is controlled effectively. The adopted remuneration process shall serve as a basis for an adequate decision with respect to services rendered as well as an appropriate incentive to the individual members of the Board of Directors, taking into account the long-term interests of the shareholders and the Company’s success. In addition, the Remuneration and Nomination Committee assists the Board of Directors in determining the principles of the remuneration strategy of BB Biotech AG.

The Remuneration and Nomination Committee submits proposals to the Board of Directors for resolution in the following areas:

  • Amount and composition of the aggregate remuneration of the Board of Directors;
  • Amount and composition of the remuneration of the Chairman of the Board of Directors;
  • Amount and composition of the remuneration of the Vice-Chairman as well as the other members of the Board of Directors;
  • Amount and composition of the additional remuneration of the members of a Board of Directors Committee.

Furthermore, the Remuneration and Nomination Committee assists the Board of Directors in resolving on conclusion, termination, or amendment of contracts entered into with external asset managers and thus in particular on the amount of the compensation to be paid under the respective contracts.

2. Remuneration of the members of the Board of Directors

2. Remuneration of the members of the Board of Directors

2.1 Principles

The remuneration of the members of the Board of Directors is based on the scope of activity and responsibility of the individual members (Chairman of the Board of Directors, Vice-Chairman of the Board of Directors, member of the Board of Directors; involvement in committees: chairmanship of a committee, member of a committee).

The remuneration of the Board of Directors consists of the following elements:

  • Fixed remuneration (disbursement by cash compensation);
  • Social insurance contributions and duties.

The limitation to a fixed remuneration ensures that the focus of the Board of Directors lies on the long-term success of BB Biotech AG. Its amount takes account of the workload and responsibility of the individual members of the Board of Directors. Therefore, the remuneration of the Board of Directors has been separated from the compensation of the investment manager; thus, the Board of Directors does not have an incentive to take excessively high risks.

Upon request of the Remuneration and Nomination Committee, the entire Board of Directors resolves once a year on the amount of the remuneration of the members of the Board of Directors and the committees.

The Board of Directors had determined the fixed remuneration of its members (as a member of the Board of Directors or a committee) as follows:

 

 

2020 in CHF

 

2019 in CHF

Function/Responsibility

 

 

 

 

Chairman

 

360 000

 

360 000

Vice-Chairman

 

250 000

 

250 000

Members

 

562 500

 

437 500

Chairman of the Remuneration and Nomination Committee

 

15 000

 

15 000

Member of the Remuneration and Nomination Committee

 

10 000

 

10 000

Chairman of the Audit Committee

 

15 000

 

15 000

Member of the Audit Committee

 

10 000

 

10 000

 

 

1 222 500

 

1 097 500

2.2 Remuneration of the individual members of the Board of Directors in the reporting year (audited)

In the reporting year 2020, the five members of the Board of Directors received a total remuneration of CHF 1 272 316 (2019: CHF 1 151 684). From this amount, CHF 1 222 500 (2019: CHF 1 097 500) have been paid in the form of a fixed remuneration for the work on the Board of Directors and on the committees of the Board of Directors. The social insurance contributions and the duties amounted to a total of CHF 49 816 (2019: CHF 54 184).

The individual members of the Board of Directors were paid the following remuneration:

Fiscal year 2020

Name/Function

 

RNC 1)

 

AC 2)

 

Period

 

Fixed remu- neration

 

Commit- tee remu- neration

 

Social insurance contributions and duties

 

Total

Hunziker Erich, Chairman

 

 

 

 

 

01.01.2020 – 31.12.2020

 

360 000

 

 

23 995

 

383 995

Meanwell Clive, Vice-Chairman

 

X

 

X

 

01.01.2020 – 31.12.2020

 

250 000

 

25 000

 

 

275 000

Galbraith Susan, Member

 

 

 

 

 

01.10.2020 – 31.12.2020

 

62 500

 

 

 

62 500

Krogsgaard Thomsen Mads, Member

 

 

 

 

 

19.03.2020 – 31.12.2020

 

187 500

 

 

 

187 500

Strein Klaus, Member

 

X

 

 

 

01.01.2020 – 19.03.2020

 

62 500

 

2 500

 

4 251

 

69 251

von Planta Thomas, Member

 

X

 

X

 

01.01.2020 – 31.12.2020

 

250 000

 

22 500

 

21 570

 

294 070

1 RNC = Remuneration and Nomination Committee (Klaus Strein until March 19, 2020, Thomas von Planta from March 19, 2020)

2 AC = Audit Committee

Fiscal year 2019

Name/Function

 

RNC 1)

 

AC 2)

 

Period

 

Fixed remu- neration

 

Commit- tee remu- neration

 

Social insurance contributions and duties

 

Total

Hunziker Erich, Chairman

 

 

 

X

 

01.01.2019 – 31.12.2019

 

360 000

 

3 750

 

23 012

 

386 762

Meanwell Clive, Vice-Chairman

 

X

 

X

 

01.01.2019 – 31.12.2019

 

250 000

 

25 000

 

 

275 000

Strein Klaus, Member

 

X

 

 

 

01.01.2019 – 31.12.2019

 

250 000

 

10 000

 

16 130

 

276 130

von Planta Thomas, Member

 

 

 

X

 

21.03.2019 – 31.12.2019

 

187 500

 

11 250

 

15 043

 

213 793

1 RNC = Remuneration and Nomination Committee

2 AC = Audit Committee (Erich Hunziker until March 21, 2019)

3. Remuneration of related parties at non-market conditions (audited)

3. Remuneration of related parties at non-market conditions (audited)

In the reporting year 2020, no remuneration which was not at arm’s length terms was paid to related parties (2019: none).

4. Remuneration of former members of the corporate bodies (audited)

4. Remuneration of former members of the corporate bodies (audited)

In the reporting year 2020, no remuneration was paid to former members of the corporate bodies (2019: none).

5. Loans and credits to the members of the Board of Directors (audited)

5. Loans and credits to the members of the Board of Directors (audited)

The articles of incorporation of BB Biotech AG do not provide that loans and credits may be granted to the members of the Board of Directors. Accordingly, no loans or credits which BB Biotech AG has granted to current or former members of the Board of Directors or to related parties were outstanding as of December 31, 2020 (December 31, 2019: none).

6. Contractual terms at retirement from BB Biotech AG

6. Contractual terms at retirement from BB Biotech AG

No member of the Board of Directors has a contract with BB Biotech AG providing for a severance payment in the event of leaving BB Biotech AG.

7. Management contracts

7. Management contracts

On behalf of the Company, the Board of Directors has entered into a management contract with Bellevue Asset Management AG (investment manager). In this contract, the investment manager commits to carry out management services relating to the investment activity and management of BB Biotech AG. The management contract is valid for an indefinite period and can be terminated by either party with a notice period of twelve months with effect as per the end of the following calendar year. The remuneration of the investment manager is determined by the respective contract and corresponds to a fixed fee of 1.1% p.a. on the average market capitalization without any additional fixed or performance-based elements.

BB Biotech AG uses cookies to improve website usability and ensure the best possible user experience.Use of cookies & disclaimer